financetom
Business
financetom
/
Business
/
Meta's AI system Llama approved for use by US government agencies
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Meta's AI system Llama approved for use by US government agencies
Sep 22, 2025 3:42 AM

WASHINGTON, Sept 22 (Reuters) - U.S. government agencies

will be able to use Meta Platforms' ( META ) artificial

intelligence system Llama, a senior administration official

said, as the Trump administration pushes to integrate commercial

AI tools into government operations.

The General Services Administration, the government's

purchasing arm, will add Llama to its list of approved AI tools

for federal agencies, said Josh Gruenbaum, the GSA's procurement

lead, in an interview ahead of announcing the initiative.

Agencies will then be able to experiment with Llama, a free

tool, with GSA's assurance that it meets the government's

security and legal standards.

Llama is a large language model capable of processing data,

including text, video, images and audio.

GSA has also signed off in recent months on AI tools from

Meta's competitors, including Amazon Web Services, Microsoft ( MSFT ),

Google, Anthropic and Open AI. The companies agreed to sell

their paid products at steep discounts and meet the government's

security requirements, GSA has said.

"It's not about currying favor," Gruenbaum said when asked

whether tech executives are giving the government discounts to

get President Donald Trump's approval. "It's about that

recognition of how do we all lock in arms and make this country

the best country it could possibly be."

Federal agencies will be able to deploy the tool to speed up

contract review or more quickly solve information technology

hiccups, among other tasks, he said.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Australia's Westpac settles auto finance class action lawsuit for $81 million
Australia's Westpac settles auto finance class action lawsuit for $81 million
Mar 14, 2025
(Reuters) - Australia's Westpac Banking Corp ( WEBNF ) has reached an A$130 million ($81.84 million) settlement on a class action lawsuit against the lender over commissions paid to auto dealers over five years, the bank said on Friday. The class action, which was filed by law firm Maurice Blackburn in 2020, claimed Westpac and St George Finance let car...
Sutro Biopharma Names New CEO; Plans to Reduce Workforce by Nearly 50% After Portfolio Review
Sutro Biopharma Names New CEO; Plans to Reduce Workforce by Nearly 50% After Portfolio Review
Mar 14, 2025
04:21 AM EDT, 03/14/2025 (MT Newswires) -- Sutro Biopharma ( STRO ) said late Thursday it appointed Jane Chung as its new chief executive and plans to nearly halve its workforce, following a strategic review of the company's portfolio. Chung, who was chief operating officer of the company, will succeed Bill Newell as CEO, effective March 13. Newell will remain...
Kering shares down 10% after appointment of Demna as Gucci designer
Kering shares down 10% after appointment of Demna as Gucci designer
Mar 14, 2025
PARIS (Reuters) - Kering shares tanked on Friday morning after the group led by Francois-Henri Pinault chose to bet on subversive in-house talent Demna to reinvigorate its Gucci label rather than hiring a big-ticket name from fashion's overheating job market. Shares fell by around 10% in early Paris session trade, underperforming French luxury peers which were trading flat following the...
Exicure Gets Patent in Australia for Potential Cancer Treatment Combination
Exicure Gets Patent in Australia for Potential Cancer Treatment Combination
Mar 14, 2025
04:20 AM EDT, 03/14/2025 (MT Newswires) -- Exicure ( XCUR ) said late Thursday it received a patent in Australia covering its combination approach to cancer treatment, specifically targeting CXCR4 and GPCRx. The patent supports the company's ongoing phase 2 clinical trial assessing the combination of GPC-100 and propranolol to treat multiple myeloma, a cancer of plasma cells. ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved